Nebraska Attorney General Jon Bruning says the state is getting more than $144,000 as part of a national settlement with a Pennsylvania drug maker.
Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses such as treating lower back pain between 2002 and 2006.
The Malvern, Pennsylvania, drug maker will pay $171.9 million in civil false claims settlements largely to the U.S. government, with $34.2 million from that total going to 47 states and the District of Columbia. Endo also agreed to pay $20.8 million as part of a deferred prosecution agreement.
Endo said it was pleased to resolve the issue and has programs in place to help it comply with the agreement.